From a pharmacokinetic perspective, ZMCs need not be optimized for maximal exposure, but rather to achieve the optimal maximum concentration (Cmax) in serum to increase intracellular zinc concentrations sufficiently to reactivate mutant p53 (above the EC50 of the tumor cell). This evidence concerns the gene TP53 and neoplasm.